Egilman AC - Search Results

1

Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.

Egilman AC, Wallach JD, Ross JS, Dhruva SS. Egilman AC, et al. JAMA Intern Med. 2018 Apr 1;178(4):567-569. doi: 10.1001/jamainternmed.2017.8016. JAMA Intern Med. 2018. PMID: 29340562 Free PMC article.

2

Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies.

Egilman AC, Wallach JD, Dhruva SS, Gonsalves GS, Ross JS. Egilman AC, et al. J Gen Intern Med. 2019 Nov;34(11):2319-2321. doi: 10.1007/s11606-019-05149-6. J Gen Intern Med. 2019. PMID: 31313117 Free PMC article. No abstract available.

3

Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors.

Egilman AC, Zhang AD, Wallach JD, Ross JS. Egilman AC, et al. Ann Intern Med. 2019 Oct 1;171(7):521-523. doi: 10.7326/M19-1085. Epub 2019 Aug 13. Ann Intern Med. 2019. PMID: 31404926 Free article. No abstract available.

4

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review.

Long AS, Zhang AD, Meyer CE, Egilman AC, Ross JS, Wallach JD. Long AS, et al. Among authors: egilman ac. JAMA Netw Open. 2021 May 3;4(5):e215731. doi: 10.1001/jamanetworkopen.2021.5731. JAMA Netw Open. 2021. PMID: 33956134 Free PMC article.

5

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.

Skydel JJ, Egilman AC, Wallach JD, Ramachandran R, Gupta R, Ross JS. Skydel JJ, et al. Among authors: egilman ac. JAMA Health Forum. 2022 May 27;3(5):e221158. doi: 10.1001/jamahealthforum.2022.1158. eCollection 2022 May. JAMA Health Forum. 2022. PMID: 35977252 Free PMC article.

6

Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration.

Egilman A, Wallach JD, Puthumana J, Zhang AD, Schwartz JL, Ross JS. Egilman A, et al. J Gen Intern Med. 2021 Oct;36(10):3281-3284. doi: 10.1007/s11606-021-06943-x. Epub 2021 Jun 15. J Gen Intern Med. 2021. PMID: 34131876 Free PMC article. No abstract available.

7

Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences.

Wallach JD, Egilman AC, Gopal AD, Swami N, Krumholz HM, Ross JS. Wallach JD, et al. Among authors: egilman ac. Res Integr Peer Rev. 2018 Jan 5;3:1. doi: 10.1186/s41073-017-0045-8. eCollection 2018. Res Integr Peer Rev. 2018. PMID: 29451557 Free PMC article.

8

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.

Wallach JD, Egilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS. Wallach JD, et al. Among authors: egilman ac. BMJ. 2018 May 24;361:k2031. doi: 10.1136/bmj.k2031. BMJ. 2018. PMID: 29794072 Free PMC article.

9

Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.

Wallach JD, Egilman AC, Ross JS, Woloshin S, Schwartz LM. Wallach JD, et al. Among authors: egilman ac. J Gen Intern Med. 2019 Apr;34(4):492-495. doi: 10.1007/s11606-018-4779-x. J Gen Intern Med. 2019. PMID: 30543020 Free PMC article. No abstract available.

10

Confidentiality Orders and Public Interest in Drug and Medical Device Litigation.

Egilman AC, Kesselheim AS, Krumholz HM, Ross JS, Kim J, Kapczynski A. Egilman AC, et al. JAMA Intern Med. 2020 Feb 1;180(2):292-299. doi: 10.1001/jamainternmed.2019.5161. JAMA Intern Med. 2020. PMID: 31657836 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page